MedTrace Logo

Validation of Multiparametric Models and Circulating and Imaging Biomarkers to Improve Lung Cancer EARLY Detection.

NCT04323579 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2020-03-26

No results posted yet for this study

Summary

CLEARLY will focus on validation of a multifactorial "bio-radiomic" protocol for early diagnosis of lung cancer that combines circulating biomarkers and radiomic analysis. It will (a) assess the role of molecular and cellular biomarkers (exosomes, protein signatures, circulating tumor cells - CTCs, microRNA) and radiomic signature, as complementary to assist early detection of lung cancer by low dose computed tomography-LDCT, using bioinformatics techniques; (b) assess the prognostic role of CTCs including the role of cells epithelial mesenchymal transition (EMT) and (c) standardize a method for genomic analysis of CTCs for early detection of treatment resistance.

Conditions

Sponsors & Collaborators

  • Casa Sollievo della Sofferenza IRCCS

    collaborator OTHER

  • University of Paris 5 - Rene Descartes

    collaborator OTHER

  • Maastricht University

    collaborator OTHER

  • Medical University of Gdansk

    collaborator OTHER

  • Erasmus Medical Center

    collaborator OTHER

  • University of Wuerzburg

    collaborator OTHER

  • Istituto Clinico Humanitas

    lead OTHER

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2021-07-01
Completion
2021-07-01

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04323579 on ClinicalTrials.gov